Skip to main content
NVCT
NASDAQ Life Sciences

Nuvectis Pharma Reports Widened Q1 Loss and Increased Cash Burn, Confirms 12-Month Runway

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$8.89
Mkt Cap
$235.511M
52W Low
$5.55
52W High
$11.15
52W Position info
60% above low
Off High info
20% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

NVCT sits 60% above its 52-week low of $5.55.

Summary

Nuvectis Pharma reported a widened net loss of $6.05 million for Q1 2026 and a significant increase in cash used in operations to $6.51 million, though management projects a cash runway of at least 12 months.


Key Events · Earnings and Guidance · NVCT

  • Widened Net Loss

    The company reported a net loss of $6.05 million for Q1 2026, a widening from $5.33 million in Q1 2025.

  • Increased Operating Cash Burn

    Net cash used in operating activities significantly increased to $6.51 million in Q1 2026, compared to $4.17 million in the prior year period.

  • Cash Position and Runway

    As of March 31, 2026, cash and cash equivalents stood at $25.13 million. Management believes this is sufficient to fund operations for at least 12 months.

  • ATM Program Update

    The company sold 831 common shares for $7 thousand under its ATM program in Q1 2026, with approximately $60.0 million remaining available for issuance.


Analysis · NVCT · Life Sciences

Nuvectis Pharma's Q1 2026 report details a widened net loss and increased cash burn, reflecting the significant costs associated with advancing its clinical-stage pipeline. While the company's cash position of $25.13 million is projected to fund operations for at least 12 months, the substantial increase in operating expenses and cash outflow highlights the ongoing need for capital. The remaining $60 million available under the At-The-Market (ATM) program provides a potential source for future financing, but continued reliance on dilutive offerings is a key consideration for investors.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NVCT was trading at $8.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $235.5M. The 52-week trading range was $5.55 to $11.15. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NVCT - Latest Insights

NVCT
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $19.42
Real-time Price: $19.72 info
Change: +$0.300 (+2%) info
Market Cap: $678.837M info
NVCT
Nov 04, 2026, 8:07 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $19.34
Real-time Price: $19.72 info
Change: +$0.380 (+2%) info
Market Cap: $678.837M info
NVCT
Nov 04, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $19.34
Real-time Price: $19.72 info
Change: +$0.380 (+2%) info
Market Cap: $678.837M info
NVCT
Oct 26, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $20.05
Real-time Price: $19.72 info
Change: -$0.330 (-2%) info
Market Cap: $678.837M info
NVCT
Sep 24, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $21.70
Real-time Price: $19.72 info
Change: -$1.98 (-9%) info
Market Cap: $678.837M info